Literature DB >> 3309545

Impaired glucose handling in active rheumatoid arthritis: relationship to the secretion of insulin and counter-regulatory hormones.

K L Svenson1, G Lundqvist, L Wide, R Hällgren.   

Abstract

An intravenous glucose tolerance test was performed in 45 untreated patients with active inflammatory rheumatoid arthritis and in age- and sex-matched healthy subjects. The mean k value in the patients, which correlated to the inflammatory activity, was 1.0 +/- 0.05 (SEM), which was significantly lower (P less than .001) than in the controls (1.8 +/- 0.09). The basal serum insulin concentration and the maximum insulin response to glucose loading were significantly higher (P less than .001 and P less than .01, respectively) in the patient group. The patients had a normal basal concentration of growth hormone in the serum, but during glucose infusion the concentration increased. The plasma glucagon level was significantly lower than in the controls (P less than .001). The urinary output of cortisol and catecholamines was normal. It is concluded that impaired glucose handling in active chronic inflammatory disease cannot be explained as a stress reaction but may be due to peripheral insulin resistance mediated by the inflammatory process. A paradoxical increase in growth hormone secretion during glucose infusion may suggest that this hormone is one factor that influences glucose handling in chronic inflammation. The pathophysiologic relevance of altered glucose metabolism and enhanced insulin secretion is uncertain but may reflect a possible link with the proposedly increased risk of atherosclerotic cardiovascular disease in rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3309545     DOI: 10.1016/0026-0495(87)90128-4

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  19 in total

1.  Improved insulin sensitivity by anti-TNFalpha antibody treatment in patients with rheumatic diseases.

Authors:  Frank C Huvers; Calin Popa; Mihai G Netea; Frank H J van den Hoogen; Cees J Tack
Journal:  Ann Rheum Dis       Date:  2007-04       Impact factor: 19.103

2.  Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion.

Authors:  Inge A M van den Oever; Alper M van Sijl; Michael T Nurmohamed
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-08       Impact factor: 5.346

Review 3.  Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis.

Authors:  Eun Ha Kang; Katherine P Liao; Seoyoung C Kim
Journal:  Curr Rheumatol Rep       Date:  2018-05-30       Impact factor: 4.592

Review 4.  The role of prolactin in the pathogenesis of autoimmune disease.

Authors:  Istvan Berczi
Journal:  Endocr Pathol       Date:  1993-12       Impact factor: 3.943

5.  Body composition, insulin, and leptin levels in patients with ankylosing spondylitis.

Authors:  Ismail Sari; Tevfik Demir; Leyla Didem Kozaci; Servet Akar; Tulay Kavak; Merih Birlik; Fatos Onen; Nurullah Akkoc
Journal:  Clin Rheumatol       Date:  2007-01-27       Impact factor: 2.980

6.  Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis.

Authors:  Lennart T H Jacobsson; Carl Turesson; Jan-Ake Nilsson; Ingemar F Petersson; Elisabet Lindqvist; Tore Saxne; Pierre Geborek
Journal:  Ann Rheum Dis       Date:  2006-12-11       Impact factor: 19.103

7.  Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis.

Authors:  Calin Popa; Frank H J van den Hoogen; Timothy R D J Radstake; Mihai G Netea; Agnes E Eijsbouts; Martin den Heijer; Jos W M van der Meer; Piet L C M van Riel; Anton F H Stalenhoef; Pilar Barrera
Journal:  Ann Rheum Dis       Date:  2007-05-01       Impact factor: 19.103

8.  Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation.

Authors:  R Roubenoff; R A Roubenoff; J G Cannon; J J Kehayias; H Zhuang; B Dawson-Hughes; C A Dinarello; I H Rosenberg
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

9.  Ankylosing spondylitis and other inflammatory spondyloarthritis increase the risk of developing type 2 diabetes in an Asian population.

Authors:  Hsin-Hung Chen; Su-Yin Yeh; Hue-Yong Chen; Cheng-Li Lin; Fung-Chang Sung; Chia-Hung Kao
Journal:  Rheumatol Int       Date:  2013-12-22       Impact factor: 2.631

10.  Hypothalamic-pituitary-adrenal axis function in ankylosing spondylitis.

Authors:  R Imrich; J Rovensky; M Zlnay; Z Radikova; L Macho; M Vigas; J Koska
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.